Clinical Trial: Lung Cancer
Study Evaluating Treatment Course Of A Short, Intense Radiation Therapy Followed By Radiofrequency Ablation For Medically Inoperable, Hard To Reach Lung Tumors
Technical Title: Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors near Central Airways
UCLA Department of Radiation Oncology is conducting a study that researches the effect of stereotactic body radiotherapy (SBRT), and radiofrequency ablation (RFA) for inoperable lung cancer near central airways. These two treatments are different types of less invasive cancer treatment usually performed independently, but we hope that by combining these two treatment options we will achieve improved local control. We hope this treatment course will be more effective and better tolerated than standard methods.
The investigator will design a treatment plan following a PET/CT planning scan consisting of 3 radiation treatment sessions, each taking less than one hour, delivered in 1 week. RFA treatment will follow one week after the last radiation treatment.
Annual PET-CT scans will be required to monitor your progress. Blood tests will be obtained at 4-6 weeks, 3 months, 6 months, and 1 year after all local therapies are completed.
- Eligible patients will have either one or two medically inoperable lung tumors near the central airway.
- The ability to understand and the willingness to sign a written informed consent are necessary.
- Patients with tumor parameters that fall outside of the inclusion criteria.
- Patients who have had prior radiation treatment to lung tumor.
- A course of chemotherapy within two weeks of first study treatment.
- Receiving current treatment through another study protocol.